- Home
- SKYE vs MVO Comparison
SKYE vs MVO Comparison
Compare SKYE & MVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SKYE | MVO |
|---|---|---|
| Founded | 2012 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Oil & Gas Production |
| Sector | Health Care | Energy |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.1M | 26.3M |
| IPO Year | 2013 | N/A |
Fundamental Metrics
Financial Performance| Metric | SKYE | MVO |
|---|---|---|
| Price | $0.71 | $1.47 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $15.00 | N/A |
| AVG Volume (30 Days) | ★ 182.2K | 136.3K |
| Earning Date | 05-08-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 17.46% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 1.46 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $0.99 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.57 | $0.97 |
| 52 Week High | $5.75 | $6.19 |
Technical Indicators
Market Signals| Indicator | SKYE | MVO |
|---|---|---|
| Relative Strength Index (RSI) | 43.02 | 34.05 |
| Support Level | $0.70 | $1.33 |
| Resistance Level | $0.84 | $1.57 |
| Average True Range (ATR) | 0.06 | 0.13 |
| MACD | -0.01 | -0.00 |
| Stochastic Oscillator | 20.95 | 10.53 |
Price Performance
Historical ComparisonAbout SKYE Skye Bioscience Inc.
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.
About MVO MV Oil Trust Units of Beneficial Interests
MV Oil Trust is a statutory trust. The trust was created to acquire and hold the net profits interest for the benefit of the Trust unitholders.